Published in Healthcare Finance, Tax and Law Weekly, November 21st, 2007
The pharmacokinetic and pharmacodynamic analysis, conducted by the University of Tennessee Health Science Center, Memphis, showed that SCH 530348 (TRA), a potent thrombin receptor antagonist, demonstrated sustained, dose- dependent, specific agonist-induced inhibition of platelet aggregation in blood samples from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.